Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.56 |
| ▸ | CDK2 | P24941 | 6/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.51 |
| ▸ | CDK7 | P50613 | 2/20 | 0.51 |
| ▸ | CCNH | P51946 | 2/20 | 0.51 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12954504 | 0.95 | GSK3B (0.56) | GSK3BCDK2CCNE1CDK7CCNH | |
| SCHEMBL13122727 | 0.89 | GSK3B (0.72) | GSK3BCDK2CCNE1 | |
| SCHEMBL14546032 | 0.89 | GSK3B (0.56) | GSK3BCDK2CCNE1CDK7CCNH | |
| SCHEMBL14545294 | 0.87 | GSK3B (0.64) | GSK3BCDK2CCNE1 | |
| SCHEMBL13290030 | 0.85 | GSK3B (0.50) | GSK3BCDK2CCNE1CDK7CCNH | |
| SCHEMBL12954560 | 0.85 | GSK3B (0.56) | GSK3BCDK2CCNE1CHEK1MAPKAPK2 | |
| SCHEMBL14545868 | 0.83 | GSK3B (0.58) | GSK3BCDK2CCNE1CDK7CCNH | |
| SCHEMBL12953997 | 0.83 | GSK3B (0.73) | GSK3BCDK2CCNE1 | |
| SCHEMBL13304881 | 0.83 | GSK3B (0.52) | GSK3BCDK2CCNE1CDK7CCNH | |
| SCHEMBL13304869 | 0.82 | GSK3B (0.77) | GSK3BCDK2CCNE1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | GSK3B 937/4885CDK2 1/4885CCNE1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.